Search - tctmd.com

Displaying 721 - 740 of 1234

Sort: Relevancy | Date

Presentation TCT 2018

The Future of Transcatheter Mitral Valve Intervention: Repair or Replace?

Presenter: Jeroen J. Bax, Stephan Windecker, Georg Nickenig

September 21, 2018

Presentation TCT 2018

Antithrombotic Therapy in Patients Undergoing TAVR

Presenter: Jeroen J. Bax, Stephan Windecker

September 21, 2018

Presentation TCT 2018

TAVR: New Indications and Unmet Needs

Presenter: Jeroen J. Bax, Stephan Windecker, Thomas Pilgrim

September 21, 2018

News Conference News TCT 2018

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

Shelley Wood

September 17, 2018

News Opinion Editor's Corner TCT 2017

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Shelley Wood

November 22, 2017

News Conference News TCT 2017

Early Pilot Study Results Show Symptom Improvement With TMVR

Michael O'Riordan

November 07, 2017

News Conference News TCT 2017

Massive Study Offers Snapshot of PCI Outcomes in Nonagenarians

Ashley Lyles

November 06, 2017

News Conference News TCT 2017

For ‘Torrential’ Tricuspid Regurgitation, Two New Transcatheter Devices Safe, Effective in Early Results

Yael L. Maxwell

November 02, 2017

News Opinion Editor's Corner TCT 2017

Live From Denver: TCT 2017, Day Four

Shelley Wood

November 02, 2017

News Conference News TCT 2017

ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure

Michael O'Riordan

November 02, 2017

Presentation TCT 2017

Adjunctive Pharmacotherapy During and After TAVR: Current Trends, New Studies, and the Case for Short-term (3-6 months) Systemic Anticoagulation

Presenter: Eberhard Grube, James B. Hermiller Jr., Pascal Vranckx

November 01, 2017

Presentation TCT 2017

A Primer of Conduction Abnormalities after TAVR: Frequency, Clinical Consequences, and Revised Management Recommendations (New Permanent Pacemakers)

Presenter: Eberhard Grube, James B. Hermiller Jr., Hemal Gada

November 01, 2017

Presentation TCT 2017

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

Presenter: Pamela S. Douglas

November 01, 2017

Presentation TCT 2017

Valve Durability after TAVR: Definitions, Surgical Valve Predicates, and Review of Available Data

Presenter: Danny Dvir

November 01, 2017

Presentation TCT 2017

The Clinical Relevance of Valve Leaflet Thickening after TAVR

Presenter: Raj Makkar

November 01, 2017

Presentation TCT 2017

Underutilization of TAVR in Minority Populations: Scope, Etiologies, and Possible Solutions

Presenter: Eberhard Grube, James B. Hermiller Jr., Oluseun Alli

November 01, 2017

Presentation TCT 2017

Shared Decision-making is an Essential Component of the Modern-era Heart Team: Rationale and Integration with TAVR Clinical Practice

Presenter: Eberhard Grube, James B. Hermiller Jr., Megan Coylewright

November 01, 2017

Presentation TCT 2017

Counterpoint More than Two TAVR Devices on Your Shelf is Unnecessary!

Presenter: Haim Danenberg

November 01, 2017

Presentation TCT 2017

30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Valve Disease Secondary to Mitral Annular Calcification or Failed Annuloplasty Rings

Presenter: Mayra Guerrero

November 01, 2017

Presentation TCT 2017

Point A Multi-Device Lesion-Specific Approach is Preferred!

Presenter: Michael J. Reardon

November 01, 2017

Advertisement

The Future of Transcatheter Mitral Valve Intervention: Repair or Replace?

Antithrombotic Therapy in Patients Undergoing TAVR

TAVR: New Indications and Unmet Needs

TCT 2018: Mitral Interventions, Stent Wars, Practical Skills, and More

My Takeaways From TCT 2017: Show Up, Keep It Civil, and Bring Your Best Self

Early Pilot Study Results Show Symptom Improvement With TMVR

Massive Study Offers Snapshot of PCI Outcomes in Nonagenarians

For ‘Torrential’ Tricuspid Regurgitation, Two New Transcatheter Devices Safe, Effective in Early Results

Live From Denver: TCT 2017, Day Four

ORBITA: PCI Offers No Symptom Improvement Over Sham Procedure

Adjunctive Pharmacotherapy During and After TAVR: Current Trends, New Studies, and the Case for Short-term (3-6 months) Systemic Anticoagulation

A Primer of Conduction Abnormalities after TAVR: Frequency, Clinical Consequences, and Revised Management Recommendations (New Permanent Pacemakers)

Hemodynamic Trends on Serial Echocardiograms after TAVR: Comprehensive 5-Year Analyses From PARTNER

Valve Durability after TAVR: Definitions, Surgical Valve Predicates, and Review of Available Data

The Clinical Relevance of Valve Leaflet Thickening after TAVR

Underutilization of TAVR in Minority Populations: Scope, Etiologies, and Possible Solutions

Shared Decision-making is an Essential Component of the Modern-era Heart Team: Rationale and Integration with TAVR Clinical Practice

Counterpoint More than Two TAVR Devices on Your Shelf is Unnecessary!

30-Day Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Valve Disease Secondary to Mitral Annular Calcification or Failed Annuloplasty Rings

Point A Multi-Device Lesion-Specific Approach is Preferred!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content